SEARCH

SEARCH BY CITATION

References

  • 1
    Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation: Diabetes, hypercholesterolemia, hypertension and obesity. Transplantation 1995; 60:10571060. MEDLINE
  • 2
    Stegall MD, Everson GT, Schroter G, Karrer FK, Bilir B, Steinberg T, Kam I. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, hypercholesterolemia without causing graft loss. Hepatology 1997; 25:173177. MEDLINE
  • 3
    Stegall MD, Wachs M, Everson GT, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate. Transplantation 1997; 64:17551760. MEDLINE
  • 4
    Everson GT, Trouillot TE, Wachs M, et al. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg 1999; 5(suppl):S48S57. MEDLINE
  • 5
    Trouillot TE, Stolpman NM, Wachs ME, et al. Mycophenolate mofetil-based immunosuppression does not increase the risk of cytomegalovirus disease in patients treated with rapid (14 day) steroid withdrawal after liver transplantation [abstract]. Hepatology 2000;343A.
  • 6
    Shrestha R, Bilir B, Trouillot T, et al. Outcome of liver transplantation in chronic hepatitis B, eAg negative patients using OKT3 induction and maintenance immunosuppression without prednisone. 1997 ASTP Program and Abstracts, 16th Annual Meeting, 1997;
  • 7
    Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999; 67:505509. MEDLINE
  • 8
    Groth CG, Backman L, Morales JM, et al. Sirolimus (Rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67:10361042. MEDLINE
  • 9
    Kahan BD for the Rapamune® US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection. Lancet 2000; 356:194202. MEDLINE
  • 10
    McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355:376377. MEDLINE
  • 11
    Wyeth-Ayerst Laboratories. Rapamune Production Information. Wyeth-Ayerst Laboratories, Princeton, NJ, 1999.
  • 12
    Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483510. MEDLINE
  • 13
    Sehgal SN. Rapamune®: Mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31:335340. MEDLINE
  • 14
    Watson CJE, Friend PJ, Jamieson NV, et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999; 67:505509. MEDLINE
  • 15
    Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20:123133. MEDLINE
  • 16
    Zhu J, Wu J, Frizell E, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117:1198204. MEDLINE